TYLER, Texas, May 08, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue," "ENvue Medical" or the "Company"), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/025,969, covering a novel drug delivery system utilizing the Company's proprietary surface acoustic wave (SAW) technology to enhance transdermal delivery of cannabinoid-based therapeutics.
The allowed claims provide broad intellectual property protection across multiple components of the combined SAW ultrasound and cannabinoid transdermal delivery system, including transdermal patch configurations, portable SAW-generating platforms, and methods shown to produce synergistic enhancement in cannabinoid absorption through the skin compared to administration via the transdermal patch alone.
Cannabinoid-based therapeutics continue to attract growing scientific, pharmaceutical, and commercial interest globally, particularly in pain management, neurology, inflammation, and chronic disease applications. ENvue Medical believes its ultrasound-based delivery platform may provide future opportunities to improve therapeutic administration and enable strategic collaborations across multiple treatment categories.
"This Notice of Allowance validates a meaningful expansion of our SAW platform into an entirely new therapeutic category,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “We believe that the USPTO's recognition of the synergistic effect between our ultrasound technology and cannabinoid transdermal delivery, and its determination that this combination was non-obvious, reflects the depth and breadth of our intellectual property portfolio. We believe this positions ENvue favorably as interest in cannabinoid-based therapeutics continues to grow, and we look forward to exploring the strategic opportunities this patent creates for the Company."
The Company believes this patent allowance further reinforces the value and versatility of its proprietary SAW technology platform and highlights the potential for future applications beyond its currently marketed products.
About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:
- ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
- ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
- Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com
Media Contact:
KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
envue@kcsa.com
